Hyloris Pharmaceuticals SA 52U.F Stock

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.